Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- Check2 days agoChange DetectedTwo new update dates (2026-04-01 and 2026-03-31) were added to the study record history, and two older dates (2026-03-06 and 2026-03-05) were removed.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check24 days agoChange DetectedAdded revision notes for v3.4.3 on 2026-03-05 and 2026-03-06; older revision v3.4.2 is listed under deletions.SummaryDifference0.3%

- Check38 days agoChange DetectedNew update entries were added for 2026-02-20, 2026-02-21, and 2026-02-24. Older update entries for 2026-02-14, 2026-02-17, and 2025-11-28 were removed.SummaryDifference0.3%

- Check45 days agoChange DetectedAdds two new study update dates (2026-02-14 and 2026-02-17) and removes two earlier dates (2026-01-15 and 2026-01-16). No core trial details, including eligibility, interventions, or outcomes, appear to be changed.SummaryDifference0.2%

- Check52 days agoChange DetectedPage now shows Revision: v3.4.2 and the older Revision: v3.4.1 notice has been removed along with a government funding status notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.